You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 16, 2024

CLINICAL TRIALS PROFILE FOR TECOVIRIMAT

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for TECOVIRIMAT

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00431951 ↗	Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	2007-02-01	The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers.
NCT00431951 ↗	Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers	Completed	SIGA Technologies	Phase 1	2007-02-01	The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers.
NCT00728689 ↗	Phase I Trial of an Investigational Small Pox Medication	Completed	National Institutes of Health (NIH)	Phase 1	2008-08-01	The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.
NCT00728689 ↗	Phase I Trial of an Investigational Small Pox Medication	Completed	SIGA Technologies	Phase 1	2008-08-01	The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.
NCT00907803 ↗	Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246	Completed	National Institutes of Health (NIH)	Phase 2	2009-06-01	The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of two clinical doses of the anti-orthopoxvirus drug, ST-246, administered as a single daily oral dose for 14 days to healthy, fed volunteers. The results of this trial determine which dose will be used in expanded pivotal safety trials.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for TECOVIRIMAT

Condition Name

Chart
Table

Condition Name for TECOVIRIMAT
Intervention	Trials
Monkeypox	6
Smallpox	4
Orthopoxviral Disease	2
Antiviral Agents	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for TECOVIRIMAT
Intervention	Trials
Monkeypox	6
Smallpox	4
Mpox (monkeypox)	1
Virus Diseases	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for TECOVIRIMAT

Trials by Country

Map
Table

Trials by Country for TECOVIRIMAT
Location	Trials
United States	33
Switzerland	2
Brazil	1
Congo, The Democratic Republic of the	1
Puerto Rico	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for TECOVIRIMAT
Location	Trials
Florida	4
California	3
Texas	2
Nebraska	2
Missouri	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for TECOVIRIMAT

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for TECOVIRIMAT
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	5
Phase 2	2
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for TECOVIRIMAT
Clinical Trial Phase	Trials
Not yet recruiting	5
Completed	4
Recruiting	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TECOVIRIMAT

Sponsor Name

Chart
Table

Sponsor Name for TECOVIRIMAT
Sponsor	Trials
SIGA Technologies	5
National Institute of Allergy and Infectious Diseases (NIAID)	3
National Institutes of Health (NIH)	2
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for TECOVIRIMAT
Sponsor	Trials
Other	16
NIH	5
Industry	5
[disabled in preview]	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.